Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. Naemi Honma, M. de Toledo Leme, E. Mello De Capitani, M. Wesley Perroud, A. de Souza Barbeiro, A. P. Salles Perroud, I. Felizardo Toro, R. Kalaf Mussi, J. Cláudio Seabra, J. Vassallo, A. Morcillo, D. Botelho Costa, L. Zambon (Campinas, Brazil; Boston, United States Of America). EGFR frequency and response to chemotherapy in a Brazilian NSCLC population. Eur Respir J 2013; 42: Suppl. 57, 4496

Member's Comments

No comment yet.

Related content which might interest you: ERCC1 and MDR1 expression and polymorphism frequency related to clinical outcome and chemotherapy response in a Brazilian sample of NSCLC patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Prevalence of mutations in Romanian patients with non-squamous lung carcinoma evaluated through next generation sequencing Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Cytology sample from EBUS-TBNA for multi-gene analysis in non-small-cell lung cancer (NSCLC) Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 EGFR mutation diagnostic program for NSCLC patients in Poland between 2011-2014 Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 RT-PCR expression of EML4-ALK oncogene in Bulgarian patients with non-small cell lung cancers Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 The role of second line chemotherapy in small cell lung cancer: A retrospective analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013